Loading Events

« All Events

  • This event has passed.

November 18, 2019 @ 5:00 pm

Share Funding Opportunities

Request for Applications: DCI Center of Cancer Immunotherapy

DCI Public Health Service Grant Logo

The Center of Cancer Immunotherapy (CCI) of the Duke Cancer Institute (DCI), under the leadership of Dr. Scott Antonia, is requesting applications from Duke Investigators interested in cancer immunotherapeutic-related research. Funding for this request for applications (RFA) is supported by a philanthropic gift from Dr. Ernest and Louise Borden.


The purpose of this grant is to support the production of pre-clinical proof-of-principle data in support of moving innovative immunotherapeutic strategies discovered by Duke basic research scientists into clinical trials.  Therefore, success will be measured by the formation of partnerships among basic, clinical, and correlative laboratory scientists, with the development of a clinical protocol and an NIH grant application to fund the clinical trial as a result.

Applicant Eligibility Requirements

This opportunity is open to all regular rank Faculty (Instructor, Research Assistant Professor, Research Associate Professor, Research Professor, Assistant Professor, Associate Professor and Professor) that are members of the DCI. Applications from new investigators (has not previously received substantial, independent funding from NIH) and early stage investigators (has completed their terminal research degree or end of post-graduate clinical training, whichever date is later, within the past 10 years and who has not previously competed successfully as PD/PI for a substantial NIH independent research award) are strongly encouraged.

Terms of Award

  • Twelve months. As the intent of this grant is to fund projects that have progressed beyond discovery, and are ready in the near term for translation, the project time will be 12 months, with an opportunity for a 12-month no-cost extension.
  • Acceptance of funds implies a firm commitment to provide a progress report (including expense report) by the deadline outlined in the notification of award (NOA) and subsequently, an annual update for a five-year follow-up period.
  • All awards, publications and presentations must acknowledge the Borden Scholars Award, the CCI and the DCI as indicated on NOA.

Award Amount

$60,000. School of Medicine extracts 15% of the award.  Actual direct funding for salaries and other research expenses will be $51,000. Budget proposals can support research staff, equipment, supplies but no principal investigator (PI) effort or travel.


RFA Announcement:  October 7, 2019

Application Deadline:  November 18, 2019

Outcome Announcement:  December 23, 2019

Project Period Start:  January 1, 2020

Review Process

Similar to National Institutes of Health (NIH) study sections, each application will be peer reviewed by at least two members of the CCI Scientific Review Committee*, followed by a review of the most meritorious applications at a roundtable discussion of the entire committee. All applicants will be informed of the outcome by December 23, 2019 (summary statements are not provided).


Research Proposals will be reviewed based on the following criteria:

  1. Innovation, novelty, and soundness of the research plan;
  2. Relevance to cancer immunotherapy;
  3. Likelihood that the project could lead to new peer-reviewed funding, as well as a budget that reflects the project plan.

Application and Submissions Instructions 

Applicants must use NIH PHS 398 forms for budget, biosketch and research format and include the following documents in the application (see https://grants.nih.gov/grants/funding/phs398/phs398.html for further details):

  1. Research Strategy (5 page limit) encompassing the following sections, in this order:
    1. The title of the grant, the name and program affiliation of the PI and (if appropriate) co-PI(s), as well as a brief abstract that includes the specific aims. Please note, there can only be one PI, but multiple co-PIs are allowed.
    2. A significance section, paying particular attention to relevance to cancer immunotherapy
    3. An innovation section
    4. A research design section, including relevant preliminary data and figures
    5. A brief statement indicating the need for the funds and an indication of how these pilot funds will assist you in obtaining peer-reviewed funding
  2. References (no page limit).
  3. Budget Pages (PHS 398 Form Page 4 and 5)
    1. A detailed budget justification is required
    2. Budget should be for 12 months totaling no more than $51,000
  4. NIH Biosketches for applicant and any faculty collaborators. The PI needs to be a standing member of the DCI; Co-PIs do not need to be DCI members.
  5. NIH Other Support documents for applicant and any faculty collaborators, including when appropriate, an explanation of whether overlap exists with the proposed CCI project.


All documents listed above must be combined into one PDF document and submitted via email to christy.arrowood@duke.edu by Monday, November 18, 2019 at 5:00 PM.


Files should be named with the investigator(s) last name, first name followed by “_CCI Borden Scholar Project”. (e.g.: “Smith, John_CCI Borden Scholar Project.pdf”)

*CCI Scientific Review Committee:

  • Scott Antonia, MD, PhD
  • Mustafa Khasraw, MD
  • Brent Hanks, MD, PhD
  • Andrew Nixon, PhD
  • Jennifer Choe, MD, PhD
  • Ahmed Galal, MD
  • Jeffrey Clarke, MD
  • Joanne Kurtzberg, MD

Questions regarding this funding announcement can be directed to Christy Arrowood 919-613-6130, christy.arrowood@duke.edu


November 18, 2019
5:00 pm
Event Category: